# Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

> **NCT01317641** · PHASE1,PHASE2 · COMPLETED · sponsor: **Orion Corporation, Orion Pharma** · enrollment: 136 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** ODM-201

## Key facts

- **NCT ID:** NCT01317641
- **Lead sponsor:** Orion Corporation, Orion Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2017-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01317641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01317641, "Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01317641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*